A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Delafloxacin (Primary) ; Aztreonam; Vancomycin
  • Indications Abscess; Bacterial skin diseases; Burn infections; Cellulitis; Erysipelas; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Skin infections; Wound infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PROCEED
  • Sponsors Melinta Therapeutics
  • Most Recent Events

    • 24 Oct 2017 Results presented in a Melinta Therapeutics media release.
    • 08 Oct 2017 Results (n=1492) of pooled analysis of this and other phase III trial assessing safety presented at the IDWeek 2017
    • 08 Oct 2017 Results (n=1042) of this and other phase III trial presented at the IDWeek 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top